Cited by 7,994Cancer Cells and MetastasisTGF-β signaling in diseasesImmune cells in cancer

Microenvironmental regulation of tumor progression and metastasis

Open access
Quail, Daniela F, Joyce, Johanna A·2013·Nature Medicine

Abstract

Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence. However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis. Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer. Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.3394

Cites

202 of 202 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Therapeutic options for deactivating CAF-mediated interaction are largely focused on using, reprogramming, or eliminating CAFs.

    “In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”

    From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [77]

    The section “Therapeutic strategies for re-educating the TME” discusses depleting stromal cells and proposes manipulating or re-educating the tumor microenvironment instead. The CAF section establishes that CAFs are tumor-microenvironment cells, but the paper does not say that therapeutic options for CAF-mediated interactions are largely focused on using, reprogramming, or eliminating CAFs specifically. No page number is available in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Stromal cells within the TME are attractive therapeutic targets because they are genetically stable with reduced risk of developing resistance.

    “Stromal cells within the TME are attractive therapeutic targets because they are genetically stable with reduced risk of developing resistance [223].”
  • The tumor microenvironment is a complex ecosystem comprised of multiple cell types that support the growth of tumor cells, facilitate tumor progression, and modulate therapeutic response to anti-cancer treatments.

    “The tumor microenvironment is a complex ecosystem comprised of multiple cell types that support the growth of tumor cells, facilitate tumor progression, and modulate therapeutic response to anti-cancer treatments [29,99,100,120,121].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Quail, D. F., & Joyce, J. A.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Joyce, Johanna A
Venue
Nature Medicine
Published
2013-11
Volume
19
Issue
11
Pages
1423-1437
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2033278321
Cited by
7,994
References
202
Citations by year
2026: 495 · 2025: 697 · 2024: 835 · 2023: 853 · 2022: 1003 · 2021: 917 · 2020: 757 · 2019: 629 · 2018: 553 · 2017: 469 · 2016: 378 · 2015: 287 · 2014: 111 · 2013: 4 · 2012: 2
FWCI
27.47
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Canadian Institutes of Health Research
  • National Cancer Institute (U54CA126518, U54CA148967)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
tumor microenvironment, tumor stroma, tumor progression, metastasis
MeSH terms
Humans, Immunotherapy, Inflammation, Macrophages, Models, Biological, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Stromal Cells, Disease Progression, Tumor Microenvironment, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review